Metagenomi Reports Significant Revenue Decline and Increased Losses in Q2 2026

Metagenomi Therapeutics, Inc. reported a significant decline in its financial performance for the second quarter of 2026, as outlined in its latest 10-Q filing. The company recorded collaboration revenue of $(257,000) for the three months ending June 30, 2026, a stark decrease from $8.5 million in the same period last year. For the first half of 2026, collaboration revenue totaled $991,000, down from $12.6 million in the prior year. The decrease is attributed primarily to a reduction in revenue from the Ionis Pharmaceuticals collaboration, which saw a drop of $8.5 million due to timing of work performed and a cumulative catch-up adjustment related to a modification of the agreement.

Operating expenses for Metagenomi also saw a decline, totaling $28.5 million for the second quarter of 2026, compared to $29.5 million in the same quarter of 2025. The company reported a loss from operations of $28.8 million for the quarter, compared to a loss of $21 million in the prior year. For the first half of 2026, the total operating expenses were $54.4 million, down from $61.4 million in the same period last year. The reduction in expenses was primarily driven by lower employee-related costs and a decrease in stock-based compensation.

In terms of strategic developments, Metagenomi underwent a corporate name change in early 2026 to better reflect its focus on advancing its preclinical programs. The company is actively pursuing its lead programs, including MGX-001, which aims to provide a curative treatment for hemophilia A. The company is on track for a regulatory submission for MGX-001 in the fourth quarter of 2026, with clinical trials expected to begin in 2027, pending regulatory clearance.

As of June 30, 2026, Metagenomi reported total assets of $173.7 million, a decrease from $221.1 million at the end of 2025. The company had cash, cash equivalents, and available-for-sale marketable securities totaling $120.7 million, which management believes will be sufficient to fund operations for at least the next 12 months. However, the company continues to face significant operating losses, with an accumulated deficit of $361.4 million as of the end of the second quarter. Looking ahead, Metagenomi anticipates the need for additional funding to support its ongoing research and development activities, as well as to cover the costs associated with operating as a public company.